PCSK9 Education and Research Forum:
ESC CONGRESS 2014 30 August - 3 September
Headlines on PCSK9 News
ODYSSEY trials shine at Hotline 2: Impressive results from four trials from the ODYSSEY Phase III Programme with alirocumab ODYSSEY FHI and FHII, ODYSSEY COMBO II, ODYSSEY LONG TERM
Send an invitation to join PCSK9 Forum to your colleagues, click here for the invite linkOur mission
Our goal
PCSK9 Education and Research Forum is the major, globally-recognised resource of independent knowledge of PCSK9 science and its translation to therapeutic innovation. Our mission is to facilitate development of these new treatments in order to transform the prognosis of millions of people with hypercholesterolaemia and accelerated atherosclerotic vascular disease.
Our response to this challenge
Established by leading researchers as a not-for-profit organisation, the PCSK9 Education and Research Forum will provide healthcare professionals with open access to electronic and multimedia platforms providing real-time reporting of significant developments and news; authoritative analysis and commentary; and, an extensive library of accredited educational materials tailored to the differing needs of a spectrum of audiences. As a result, the Forum will expand awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.
Our partnership and outreach
Through its unique global network of researchers and clinicians, the PCSK9 Education and Research Forum will reach out to academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of CVD mortality and morbidity through improved management of atherosclerotic dyslipidaemia. The Forum will establish educational partnerships with such organisations through jointly sponsored symposia as well as accredited research and educational programmes. |
|
|
